Format

Send to

Choose Destination
J Obstet Gynaecol. 2011 Aug;31(6):465-72. doi: 10.3109/01443615.2011.579197.

Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.

Author information

1
The Motherisk Program, Department of Pediatrics, Hospital for Sick Children, and Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.

Abstract

Studies of 1st trimester exposure to ACE inhibitors and angiotensin receptor blockers examining teratogenicity have shown conflicting results. We systematically reviewed the literature and performed a meta-analysis evaluating the risk of major malformations. For the meta-analysis, we included studies comparing 1st trimester exposure to no exposure, or to exposure to other antihypertensives. Additionally, we conducted a qualitative analysis of studies that did not meet the inclusion criteria for the meta-analysis. A significant risk ratio was found when the exposed group was compared with healthy controls but not when compared with other antihypertensives. The qualitative analysis did not demonstrate a specific pattern of major malformations. Our results suggest that 1st trimester exposure to ACE inhibitors and angiotensin receptor blockers is not associated with an elevated risk of major malformations compared with other antihypertensives. A 1st trimester exposure to antihypertensives in general may be associated with an elevated risk of major malformations.

PMID:
21823839
DOI:
10.3109/01443615.2011.579197
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center